PanTher Therapeutics Closes Oversubscribed $5.4M Series A Round, Expands Board of Directors, As Company Prepares to Initiate First Clinical Trial of Novel Localized Treatment of Pancreatic Cancer

PanTher Therapeutics, a privately held oncology company revolutionizing the treatment of solid tumors through direct, localized, and sustained delivery of proven and novel therapeutic agents, announces today that it has closed an oversubscribed $5.4M Series A round led by Catalyst Health Ventures (CHV), with participation by Angel Physicians Fund (APF) and other notable investors. The Series A round brings the total amount raised by the company to $7.4M.

PanTher’s novel approach empowers oncologists to treat patients with life-threatening cancers by unlocking a drug’s full potential through direct, sustained treatment at the tumor site. The company’s proprietary platform is based on technology that was developed at the Massachusetts Institute of Technology (MIT) and was subsequently in-licensed by PanTher.

PanTher’s lead candidate is designed to control tumor progression in pancreatic cancer and improve survival rates, and it is easily integrated into a commonly used, minimally invasive staging procedure. PanTher’s platform technology can be adapted to treat additional solid tumor indications.

In 2018, PanTher became an inaugural awardee of the MLSC’s Massachusetts Next Generation Initiative (MassNextGen), a five year, more than $2 million commitment to ensure greater gender parity in the next generation of life science entrepreneurs.

Share This Post

21267
MLSC Brandmark scaled 1